Usted está a punto de salir de la página web de GSK

Este enlace lo llevará a un sitio web que no pertenece a GSK. GSK no recomienda, aprueba ni acepta responsabilidad por los sitios controlados por terceros.

Continuar

Regresar

Summary Slide Sets

TRIUMEQ data overview

Go To Close Top

A review of the data for Triumeq (dolutegravir/abacavir/lamivudine) that includes efficacy, tolerability, resistance, drug interactions and convenience.

Download>>

IAS Sets

Age

IAS Age

People aged >50 years living with HIV

Download>>

Race

IAS Race

Race/ethnicity

Download>>

Women

IAS Women

Women living with HIV

Download>>

Summary Slide Sets

SINGLE – 144 Weeks

SINGLE – 144 Weeks

How does a dolutegravir-based regimen compare to Atripla® in treatment-naïve patients at 144 weeks?

Download>>

SINGLE – 96 Weeks

SINGLE – 96 Weeks

How does a dolutegravir-based regimen compare to Atripla® in treatment-naïve patients at 96 weeks?

Download>>

FLAMINGO – 96 Weeks

FLAMINGO – 96

Efficacy and safety of a dolutegravir-based regimen versus a darunavir/r regimen in treatment-naïve subjects

Download>>

Bioequivalence Study

Bioequivalence Study

Triumeq (DTG/ABC/3TC single-pill) bioequivalence study

Download>>

TRIUMEQ, TIVICAY, ZIAGEN, EPIVIR, KIVEXA, EPZICOM, TRIZIVIR, COMBIVIR
son marcas registradas del grupo de compañías ViiV Healthcare